Mississauga, ON -- (ReleaseWire) -- 06/06/2014 --AllPennyStocks.com Media, Inc. (http://www.AllPennyStocks.com/) announces its latest article titled “First Patient Enrolled in BrainStorm Cell Therapeutics Phase 2 Trial of Amyotrophic Lateral Sclerosis Therapy.”

Companies mentioned in this article include BrainStorm Cell Therapeutics Inc. (OTCQB:BCLI).

Article Excerpt:

Many in the biotech community have held that some of the greatest promise for regenerative medicine therapies may rest in their uses for neurodegenerative disorders, diseases such as Alzheimer’s, Huntington’s, Parkinson’s and Amyotrophic Lateral Sclerosis for which traditional therapies provide no real solutions. That’s not to discount the potential benefits of stem cell therapies across a wide array of diseases and conditions, such as stroke and heart disease; only to highlight that neurodegenerative disorders represent a tremendous area of unmet medical need for which regenerative medicine could make a clinical difference. Research on stem cells, which was fought tooth-and-nail by too many for too long, is starting to unwind some of the mysteries and landmarks in cell development, which can be integral to viable therapies in the future.

BrainStorm Cell Therapeutics Inc. (OTCQB:BCLI) is hoping to deliver the first stem cell therapeutic for Amyotrophic Lateral Sclerosis (ALS, or “Lou Gehrig’s Disease” as it’s often called), a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord and one of the most common neuromuscular diseases in the world. ALS is a painful disease to watch someone suffer, and eventually die from, as motor neurons rapidly degenerate, halting communication with muscles that eventually atrophy, leaving the afflicted with difficulty talking, swallowing or breathing and sometimes totally paralyzed before death. While physical functions are destroyed, cognitive function and all the senses often remain unaffected.

The full version of this article can be found at:
http://www.allpennystocks.com/aps_us/special-reports/450/first-patient-enrolled-in-brainstorm-cell-therapeutics-phase-2-trial-of-amyotrophic-lateral-sclerosis-therapy.htm

About AllPennyStocks.com
AllPennyStocks.com is focused on the small-cap / penny stock market and has become a reputable name in the investment community. AllPennyStocks.com runs a Canadian and US site to provide investors in Canada as well as the United States with informative and unique content and information. AllPennyStocks.com runs daily technical penny stocks to watch, has a daily market write-up, provides company spotlights, runs unique most active pages strictly for penny stocks trading on the TSX, TSX Venture, NASDAQ and OTC BB, and much more information for the average investor.

AllPennyStocks.com also runs an email newsletter that aims to uncover stocks that are still under the radar of most investors. Criteria AllPennyStocks.com looks for includes strong revenues, a seasoned management, innovative business plans, among many others. AllPennyStocks.com also looks for companies that announce breaking news, recent 52-week highs/lows, technical breakouts, and other favorable corporate information.

Investors are encouraged to subscribe to the AllPennyStocks.com FREE e-mail newsletter and see what tens of thousands of other investors have already been receiving since 1999. Investors can receive their free newsletter subscription by clicking here: http://www.allpennystocks.com/aps_common/newsletter_free.asp.

Contact:

AllPennyStocks.com Media, Inc.
Peter Szafranski -- President
Phone: (905) 361-5680
E-Mail: peter@allpennystocks.com
Websites: http://www.allpennystocks.com / http://www.bullishinvestor.com

Note: AllPennyStocks.com has not received compensation for carrying the above-mentioned company; a full disclaimer can be viewed here: http://www.allpennystocks.com/aps_common/disclaimer.asp.